Abstract
The COVID-19 pandemic is ongoing as of mid-2022 and requires the development of new therapeutic drugs, because the existing clinically approved drugs are limited. In this work, seven derivatives of epoxybenzooxocinopyridine were synthesized and tested for the ability to inhibit the replication of the SARS-CoV-2 virus in cell cultures. Among the described compounds, six were not able to suppress the SARS-CoV-2 virus’ replication. One compound, which is a derivative of epoxybenzooxocinopyridine with an attached side group of 3,4-dihydroquinoxalin-2-one, demonstrated antiviral activity comparable to that of one pharmaceutical drug. The described compound is a prospective lead substance, because the half-maximal effective concentration is 2.23 μg/μL, which is within a pharmacologically achievable range.
Keywords: SARS-CoV-2; antiviral activity; epoxybenzooxocinopyridine derivatives.
【저자키워드】 SARS-CoV-2, antiviral activity, epoxybenzooxocinopyridine derivatives., 【초록키워드】 Antiviral, COVID-19 pandemic, drugs, SARS-CoV-2 virus, antiviral activity, Replication, therapeutic, compounds, approved drug, derivative, cell cultures, derivatives, half-maximal effective concentration, Seven, tested, described, clinically, inhibit, demonstrated, comparable, suppress, the SARS-CoV-2 virus, 【제목키워드】 synthesis, property,